Dr.Stan Kaye – Best Costs, Reviews – Book Your Consultation

Professional Experience

• Consultant Medical Oncologist at The Royal Marsden, London
• Head of the Drug Development Unit jointly between Royal Marsden and Institute of Cancer Research (ICR)
• Previously, in 1985, appointed Head of the Department of Medical Oncology at University of Glasgow, where he established a clinical trials unit
• Co-founder of the Scottish Gynaecological Cancer Trials Group in 1986
• Chair of the NIHR Oncology Translational Research Collaboration (O-TRC) from 2021 to facilitate multicentre cancer studies
• Awarded Cancer Research UK Lifetime Achievement in Cancer Research in 2016 for his contributions to drug development and ovarian cancer treatment

Academic Contributions

• Emeritus Professor at the Institute of Cancer Research (ICR) in London
• Supervision and mentorship of multiple generations of oncologists and clinical scientists
• Frequent lecturer, course leader, and invited speaker at national and international oncology meetings
• Served on editorial boards of oncology journals (≈ 12 journals)
• Editor (or co-editor) of “Emerging Therapeutic Targets in Ovarian Cancer” and contributor to cancer therapy textbook chapters

Areas of Expertise

• Ovarian and gynaecological cancers — especially design and testing of new therapeutic agents
• Early-phase (Phase I/II) clinical trials of novel agents and combinations
• Mechanisms of drug resistance and translational biomarker development
• Targeted therapies (e.g. PARP inhibitors) and precision oncology strategies
• Other solid tumours and systemic therapies including chemotherapeutics like capecitabine and docetaxel

Publications and Research

Patient Care Philosophy

• Emphasis on clear communication: explaining complex treatments in accessible terms for patients
• Patient education and shared decision-making: ensuring patients understand benefits and risks
• Culturally sensitive care and considering patients from diverse backgrounds, including international referrals
• Commitment to patient safety, rigorous trial ethics, and maximizing quality of life
• Strong focus on mentorship and involving patients in research advances ethically

Professional Affiliations

• Fellow of the Royal Colleges (FRCP, FRCR)
• Fellow of the Royal Society of Edinburgh (FRSE)
• Fellow of the Academy of Medical Sciences (FMedSci)
• Leadership roles in Cancer Research UK, including chairing clinical trials committees
• Chair of the NIHR Oncology Translational Research Collaboration (O-TRC)

FAQs

Is Stan Kaye board-certified?

Yes — he holds fellowships and certifications with UK Royal Colleges in medical oncology (FRCP, FRCR) and is widely recognized by professional bodies.

What types of therapies or trials does he perform?

He specializes in early-phase clinical trials (Phase I/II) of novel cancer therapies, targeted agents such as PARP inhibitors, and combination regimens across solid tumours, particularly ovarian cancer.

Does he treat international patients?

Yes — as part of a leading cancer research centre with global reach, the Royal Marsden and ICR accept referrals internationally. His expertise in translational oncology attracts patients from around the world.

How long is the typical hospital stay?

Hospital stays depend on the type of treatment. Many early-phase trial visits are outpatient or short stay, while more complex treatments may require longer monitoring.

What languages does he speak?

Public sources do not list additional languages. His primary professional language is English, which is the standard in UK clinical settings.

Does Professor Kaye focus only on ovarian cancer?

No — while ovarian and gynaecological cancers are his primary focus, he has contributed to the development of therapies for a range of solid tumours through clinical trials and translational research.

Is Professor Kaye still active in research?

Yes — although now Emeritus Professor, he continues to contribute through mentorship, advisory roles, and leadership in collaborative oncology research initiatives.